Sun Pharma Advanced Research Company Quarterly Results

Charts

YoY Net Sales (Quarterly)

Operating Margin

EPS Growth

POSITIVES

Revenue increased slightly in the latest quarter, suggesting potential recovery or growth.
Other income showed a significant rise in Q2 2025, indicating better revenue diversification.
Reduction in net profit loss in the latest quarter shows improving cost management.

NEGATIVES

Net profit remains negative, indicating ongoing financial distress.
Operating profit continues to decline, raising concerns over core business profitability.
High expenses persist, particularly in material costs, impacting overall performance.

Field	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25
Revenue	21.18	13.86	16.56	16.81	12.86	14.91	27.19	9.64
Expenses	116.09	119.90	126.37	113.87	120.07	94.54	87.86	70.59
Operating Profit	-94.91	-106.04	-109.81	-97.06	-107.21	-79.63	-60.67	-60.95
Other Income	8.49	6.39	4.40	1.56	0.04	0.19	0	9.14
Interest	0.26	0.26	0.91	0.56	1.14	2.80	4.54	6.19
Depreciation	3.18	3.16	3.07	3.14	3.16	3.14	2.95	2.68
Profit Before Tax	-86.42	-99.65	-105.41	-95.50	-107.17	-79.44	-60.67	-51.81
Tax	0	0	0.38	0.40	0.16	0.07	-0.90	0.06
Net Profit	-86.42	-99.65	-105.79	-95.90	-107.33	-79.51	-59.77	-51.87
Eps in Rs	-2.66	-3.07	-3.26	-2.96	-3.31	-2.45	-1.84	-1.60